Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • childhood obesity

    - PMLiVE

    Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

    As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

    Inizio

    - PMLiVE

    Eli Lilly’s oral weight-loss candidate orforglipron shows promise in late-stage trial

    The company is planning to submit the candidate for regulatory review by the end of the year

    Woman holding weight loss injection

    Why patients drop out of weight management trials and what you can do about it

    Discover the key barriers to retention in obesity and weight-management trials and explore actionable, patient-centered strategies to improve engagement, outcomes, and data reliability.

    Cuttsy + Cuttsy

    - PMLiVE

    Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

    The companies will launch four development programmes for potential small molecule therapies

    - PMLiVE

    Eli Lilly’s Zepbound shows superiority in head-to-head weight loss study

    Patients treated with Lilly’s drug achieved an average weight reduction of 20.2%

    - PMLiVE

    Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

    The company is expecting to file for the first regulatory approval of the drug next year

    - PMLiVE

    Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn

    The companies will develop petrelintide as both a standalone therapy and in combination with Roche’s CT-388

    - PMLiVE

    Novo shares promising results for high-dose semaglutide in late-stage obesity study

    The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

    - PMLiVE

    Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases

    The partners are aiming to develop new drugs for type 2 diabetes, obesity and cardiovascular disease

    - PMLiVE

    Eli Lilly announces $3bn expansion to US injectables manufacturing facility

    The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

    - PMLiVE

    Amgen’s investigational weight-loss drug MariTide shows promise in mid-stage study

    The company has announced a phase 3 programme across obesity and related conditions

    - PMLiVE

    Eli Lilly and HAYA Therapeutics enter metabolic condition partnership worth $1bn

    The companies will aim to discover regulatory genome targets for obesity and related metabolic conditions

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links